Listen
TARCEVA
-
Opinions on drugs -
Posted on
Jun 06 2012
- Updated on
Jun 22 2012
Reason for request
Inclusion on the list of medicines refundable by National Health Insurance and approved for hospital use in the extension of indication “first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR activating mutations”.
-
Clinical Benefit
| Substantial |
The actual benefit of TARCEVA in this indication is substantial. |
Clinical Added Value
| minor |
In the first-line indication of the treatment of NSCLC with EGFR activating mutations, TARCEVA, like IRESSA, provides a minor improvement in actual benefit (level IV) compared to platinum-based chemotherapy. |
English version
Contact Us
Évaluation des médicaments
